FDA approves RHA Redensity Eye for undereye hollows

The FDA approved RHA Redensity Eye on August 20, 2026, giving injectors a highly stretchable hyaluronic acid option specifically indicated for treating moderate to severe undereye hollows in patients aged 22 and older. This approval expands the Teoxane RHA collection distributed by Revance, introducing a formulation designed to respect the high-mobility infraorbital area. In a 52-week US pivotal clinical study, 93% of patients showed aesthetic improvement at 3 months, with results persisting up to 12 months without touch-ups. Notably, this is the first hyaluronic acid gel to use patient-reported outcomes as a co-primary endpoint in a US clinical trial for this delicate zone. Safety data offers peace of mind when discussing the treatment with hesitant patients, as the trial reported no late-onset or serious treatment-related adverse events, and zero cases of vascular occlusion. For your clinic, this adds a predictable, structural option for the tear trough that addresses the common patient fear of unnatural stiffness or late-stage swelling in the periorbital region.

Source: Dermatology Times, https://www.dermatologytimes.com/view/fda-clears-rha-redensity-eye-for-undereye-hollows-offering-soft-stretchable-ha-filler